Psca: prostate stem cell antigen and uses thereof
CA 2566516 C · Owner: The Regents Of The University Of California · Inventors: Witte, Owen; Reiter, Robert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a novel prostate cell-surface antigen designated Prostate Stem Cell Antigen (PSCA) which is widely over-expressed across all stages of prostate cancer including high grade prostatic intraepithelial neoplasia (PIN) androgen-dependent and andro-gen-independent prostate tumors. It also provides antibodies to PSCA. Further methods of detection/diagnosis and treatment as well as a transgenic animal are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 2, 1999 and granted March 31, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 2, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 2, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.